StocktoriaARTELO BIOSCIENCES, INC. ARTL
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$11.4M | -$10.1M | -$9.9M | -$10.3M | -$9.4M |
| Net income | -$12.9M | -$9.8M | -$9.3M | -$10.1M | -$9.4M |
| Operating cash flow | -$8.5M | -$8.3M | -$8.2M | -$8.0M | — |
| Total assets | $2.8M | $4.7M | $13.0M | $20.4M | $28.3M |
| Total liabilities | $4.1M | $1.8M | $1.3M | $1.0M | $1.1M |
| Shareholders' equity | -$1.3M | $2.9M | $11.8M | $19.4M | $27.2M |
| Ratios | |||||
| Return on assets | -459.8% | -209.2% | -71.2% | -49.4% | -33.3% |
| Return on equity | 1012.5% | -343.9% | -79.0% | -52.0% | -34.6% |
| Current ratio | 0.17 | 1.44 | 8.51 | 18.36 | 23.96 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001621221 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.